Verified employee & interview reviews

Gland Pharma Reviews

Hyderabad, Telangana

4.0/ 5

1 review

Gland Pharma Limited is a prominent Indian specialty injectable-focused pharmaceutical company and a leading global player in the Contract Development and Manufacturing Organization (CDMO) space. Established in 1978 in Hyderabad, India, by P.V.N. Raju, the company has evolved from a domestic contract manufacturer of small-volume liquid parenterals into one of the world's largest and fastest-growing generic injectable companies, with a commercial footprint extending across more than 60 countries, including highly regulated markets such as the United States, Europe, Canada, and Australia. The company operates primarily under a business-to-business (B2B) intellectual property-led model. Instead of direct retail marketing, Gland Pharma partners with global pharmaceutical majors, wholesalers, distributors, and hospital networks through long-term supply contracts and profit-sharing arrangements. Its comprehensive operational capabilities span the entire value chain, including pharmaceutical research and development, dossier compilation, technology transfer, and large-scale manufacturing of complex finished dose formulations. The company's diversified delivery systems include liquid vials, lyophilized vials, pre-filled syringes (PFS), ampoules, intravenous (IV) bags, and ophthalmic drops. In terms of infrastructure, Gland Pharma operates a robust manufacturing network comprising 11 plants across India and Europe, which encompass both advanced formulation facilities and Active Pharmaceutical Ingredient (API) plants. Its landmark formulation facilities in Dundigal and Pashamylaram near Hyderabad have a long history of compliance and regulatory approvals from leading global bodies, including the US Food and Drug Administration (USFDA). Following the strategic acquisition of the French CDMO Cenexi in 2023, Gland Pharma successfully expanded its manufacturing footprint into Europe, accelerating its technical offerings in high-growth, complex areas such as oncology, biologics, and specialized sterile liquid fill-finish services. Efforts are also underway to scale capabilities in peptides, long-acting injectables, suspensions, and new delivery systems like pens and cartridges. Financially and structurally, Gland Pharma became a public limited company in 1994 and was formally listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in 2020 under the ticker GLAND. A defining milestone occurred in 2017 when Shanghai Fosun Pharmaceutical (Group) Co., Ltd. acquired a majority stake in the company, positioning it as a key subsidiary of the global pharmaceutical major. For the fiscal year ending March 31, 2025, Gland Pharma reported a consolidated revenue from operations of INR 5,830 crore. The organization is led by Executive Chairman Srinivas Sadu and CEO Shyamakant Giri, supported by a workforce of over 4,300 employees and hundreds of R&D scientists dedicated to providing affordable, high-quality injectable products globally.